Watch Ticker

Aprea Therapeutics, Inc. Common stock

Go to Aprea Therapeutics, Inc. Common stock Website

$1.70

0.06 (3.66%)

Live

Previous Close

$1.64

Day Range

$1.55 - $1.7849

Previous Day Range

$1.62 - $1.82

Market Cap

$9.9 million USD

Day Vol.

102380

Previous Day Vol.

69862

Currency

USD

Primary Exchange

Nasdaq

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for sol...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Aprea Therapeutics reported positive preclinical and early-stage clinical data for its next-generation WEE1 inhibitor, APR-1051, in treating HPV-positive head and neck squamous cell carcinoma. The drug showed potent single-agent activity and enhanced synergy with anti-PD-1 therapies in preclinical models, and demonstrated early disease control in a Phase 1 trial.

Related tickers: APRE.

Read Full Article

N/A - Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Aprea Therapeutics reported progress in its clinical trials for ATRN-119 and APR-1051, with early evidence of anti-tumor activity and continued enrollment. The company has sufficient cash runway into early Q2 2026.

Related tickers: APRE.

Read Full Article

Trending Tickers

Please sign in to view